Loading...
XJPX4530
Market cap1.90bUSD
Dec 26, Last price  
4,091.00JPY
1D
0.64%
1Q
3.31%
Jan 2017
-30.07%
Name

Hisamitsu Pharmaceutical Co Inc

Chart & Performance

D1W1MN
XJPX:4530 chart
P/E
21.48
P/S
2.12
EPS
190.46
Div Yield, %
2.19%
Shrs. gr., 5y
-1.62%
Rev. gr., 5y
-0.24%
Revenues
141.71b
+10.42%
83,545,000,000102,665,000,000109,791,000,000119,061,000,000124,655,000,000129,834,000,000137,184,000,000137,794,000,000142,772,000,000150,635,000,000156,743,000,000161,852,000,000145,925,000,000147,870,000,000143,408,000,000140,992,000,000114,510,000,000120,193,000,000128,330,000,000141,706,000,000
Net income
13.97b
+18.97%
12,873,000,00014,448,000,00015,847,000,00018,663,000,00019,120,000,00018,423,000,00020,956,000,00018,439,000,00018,809,000,00021,357,000,00018,784,000,00017,784,000,00020,395,000,00019,119,000,00019,204,000,00018,694,000,0009,250,000,0009,658,000,00011,742,000,00013,969,000,000
CFO
18.19b
+42.91%
20,130,000,00023,114,000,00012,228,000,00025,722,000,00022,382,000,00020,498,000,00036,342,000,00025,558,000,00032,485,000,00035,845,000,00023,232,000,00030,923,000,00019,910,000,00030,453,000,00015,772,000,00027,395,000,0005,289,000,00019,199,000,00012,727,000,00018,188,000,000
Dividend
Feb 27, 20250 JPY/sh
Earnings
Jan 09, 2025

Profile

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
URL
https://www.hisamitsu.co.jp/
IPO date
Sep 01, 1962
Employees
2,769
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑022023‑022022‑022021‑022020‑022019‑022018‑022017‑022016‑022015‑02
Income
Revenues
141,706,000
10.42%
128,330,000
6.77%
120,193,000
4.96%
Cost of revenue
128,538,000
116,729,000
110,856,000
Unusual Expense (Income)
NOPBT
13,168,000
11,601,000
9,337,000
NOPBT Margin
9.29%
9.04%
7.77%
Operating Taxes
4,754,000
3,987,000
3,093,000
Tax Rate
36.10%
34.37%
33.13%
NOPAT
8,414,000
7,614,000
6,244,000
Net income
13,969,000
18.97%
11,742,000
21.58%
9,658,000
4.41%
Dividends
(6,578,000)
(6,719,000)
(6,839,000)
Dividend yield
2.21%
2.22%
2.30%
Proceeds from repurchase of equity
(9,796,000)
(7,755,000)
(8,127,000)
BB yield
3.28%
2.56%
2.73%
Debt
Debt current
1,421,000
1,398,000
1,372,000
Long-term debt
1,632,000
1,974,000
2,258,000
Deferred revenue
9,000
8,408,000
8,216,000
Other long-term liabilities
10,568,000
1,817,000
2,342,000
Net debt
(189,389,000)
(202,740,000)
(199,934,000)
Cash flow
Cash from operating activities
18,188,000
12,727,000
19,199,000
CAPEX
(12,924,000)
(7,908,000)
(4,193,000)
Cash from investing activities
(2,512,000)
(23,868,000)
(13,060,000)
Cash from financing activities
(16,691,000)
(14,687,000)
(15,189,000)
FCF
(2,786,000)
9,305,000
10,791,000
Balance
Cash
125,321,000
136,868,000
142,431,000
Long term investments
67,121,000
69,244,000
61,133,000
Excess cash
185,356,700
199,695,500
197,554,350
Stockholders' equity
301,708,000
502,446,000
499,547,000
Invested Capital
94,387,300
68,890,500
67,407,650
ROIC
10.31%
11.17%
8.91%
ROCE
4.63%
4.29%
3.47%
EV
Common stock shares outstanding
77,003
79,406
81,270
Price
3,874.00
1.41%
3,820.00
4.37%
3,660.00
-44.88%
Market cap
298,309,622
-1.66%
303,330,920
1.98%
297,448,200
-45.23%
EV
111,125,622
321,839,920
326,725,200
EBITDA
18,340,000
16,553,000
13,658,000
EV/EBITDA
6.06
19.44
23.92
Interest
18,000
15,000
20,000
Interest/NOPBT
0.14%
0.13%
0.21%